Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Hosted on MSN1d
APAC to boost pharmaceutical growth with increased R&D investments
South Korea allocated 5.2% of its GDP to R&D in 2024. Increasing public and private research and development (R&D) ...
News Medical1d
New AI hub for healthcare and neuromodulation set to launch in Geneva
The University hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva and the Wyss Center for Bio and Neuro Engineering enter into a three-party agreement to ...
FAD AGENCY - FAD Magazine1d
Beyond Humanity: Yuqiang Chen’s Technological Critique and Bio-Aesthetic Experimentation
His works are not only profound reflections on the implications of biotechnology and identity in future societies but also a ...
Today’s contemporary Black artists continue a legacy of transformation with their work
There are countless examples of the ways that Black creativity in America has literally changed the world — from jazz, rock, ...
Modesto Bee4d
From fashion to finance, Modesto high schools offer over a dozen career and technical paths
All high schools, including Elliot Alternative, offer the design, visual and media arts pathway. Davis, Downey, Gregori and ...
News Medical6d
Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials
Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...